Basilea partners antifungal agent

Thursday 25 February 2010

Basilea Pharmaceutica Ltd has partnered its Phase 3 antifungal agent, isavuconazole, with Astellas Pharma Inc of Japan, making it eligible for an upfront payment of CHF75 million (€51 million).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland